• PCR83 Fibrodysplasia Ossificans Progressiva (FOP): The Patient Experience

    Dec 1, 2023, 00:00

  • EE184 Lessons Learned from Model-Based Economic Evaluations of COVID-19 Treatments Under Pandemic Circumstances: Results from a Systematic Review

    Dec 1, 2023, 00:00

  • CO99 Real-Life Effectiveness of Ibrutinib in Chronic Lymphocytic Leukemia

    Dec 1, 2023, 00:00

  • EE538 Hospital Budget Impact of a Lung Suite Navigation Platform to Diagnose and Treat Lung Cancer Patients

    Dec 1, 2023, 00:00

  • EPH132 Epidemiology of Breast and Cervical Cancer in Women of the Colombian Caribbean Region During 2018-2021

    Dec 1, 2023, 00:00

  • EE605 Methodological Acceptability of the Economic Analyses Assessed by the HAS in 2022

    Dec 1, 2023, 00:00

  • EE277 Assessing the Cost-Effectiveness of Semaglutide 2.4 Mg Injection for Chronic Weight Management in Portugal

    Dec 1, 2023, 00:00

  • Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0

    Dec 1, 2023, 00:00

  • MSR37 Validation of the Ibadan Knee/Hip Osteoarthritis Outcome Measure (IKHOAM) Among Patients With Knee Osteoarthritis

    Dec 1, 2023, 00:00

  • EE397 Determinants of Higher Cost and Inpatient Hospitalization Among Patients with AL Amyloidosis

    Dec 1, 2023, 00:00

  • EE751 Economic Evaluation of Hepatitis B Vaccination Programme in Finland

    Dec 1, 2023, 00:00

  • HTA184 Review of HTA Evaluation for Gene Therapies and Their Future Implications in Europe

    Dec 1, 2023, 00:00

  • PCR54 Knowledge, Attitudes and Practices of Patients Towards Generics in Greece

    Dec 1, 2023, 00:00

  • EPH104 Human Papilloma Virus (HPV) Vaccination: Financial Impact and Recommendations

    Dec 1, 2023, 00:00

  • CO148 Effectiveness of Tocilizumab in Refractory Graves' Orbitopathy in a Real-World Setting

    Dec 1, 2023, 00:00

  • PCR254 Building a COA Strategy in Chronic Rhinosinusitis with or Without Nasal Polyps: Patient Experiences and Clinical Outcome Assessments from the Literature

    Dec 1, 2023, 00:00

  • RWD143 Beyond Accuracy: Automated De-Identification of Large Real-World Clinical Text Datasets

    Dec 1, 2023, 00:00

  • EE151 Trade-Off between Comparators Comprehensiveness and Methodological Robustness in Cost-Utility Studies Reviewed By Has in France

    Dec 1, 2023, 00:00

  • HTA199 Digital Health Application (DiGA) vs Other Digital Health Technologies (DHT) as Part of Disease Management Programs (DMP)—Assessment Requirements in Germany Diverge Between HTA Authorities

    Dec 1, 2023, 00:00

  • HTA73 Health Technology Assessment (HTA) Timelines Analysis in the Post-COVID Era: Comparison of HTA Process Duration in the First Half (H1) of 2023 to H1 2022

    Dec 1, 2023, 00:00

  • PCR258 Baseline Demographic and Clinical Characteristics of Patients with Plaque Psoriasis Treated with Brodalumab in the Canadian Real-World Setting: Results from the Care Study

    Dec 1, 2023, 00:00

  • EE111 Indirect Cost Burden for Individuals Living with Transfusion-Dependent Beta-Thalassemia in Europe

    Dec 1, 2023, 00:00

  • Table of Contents

    Dec 1, 2023, 00:00

  • HSD87 Physician Reported Reasons for Cidp Treatment Choice across 5 European Countries: Results from a Real-World Survey

    Dec 1, 2023, 00:00

  • HTA65 Economic Evaluation of Medical Devices By the French National Authority (2014-2022): Where Do We Stand?

    Dec 1, 2023, 00:00

  • MSR60 Use of External Control Arms (ECAs) in Marketing Applications Submitted to European Medicines Agency (EMA): A Targeted Review

    Dec 1, 2023, 00:00

  • EE692 Cost-Effectiveness of Nivolumab (NIVO) and NIVO in Combination With Ipilimumab (IPI) in First-Line Treatment of Advanced Melanoma in Colombia: Analysis Using 78-Month Overall Survival From CheckMate 067

    Dec 1, 2023, 00:00

  • EE448 Exploring Non-Patient Utilities Using Time Trade-Off Exercises in the UK General Population

    Dec 1, 2023, 00:00

  • HTA7 Exploring the Predictive Accuracy of Treatment Waning Methods: An Analysis of Pembrolizumab across Six Oncology Indications

    Dec 1, 2023, 00:00

  • EE520 Hospital Costs in Resected Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC): A French Real-World Retrospective Study Based on the National Hospitalization Database (PMSI)

    Dec 1, 2023, 00:00

  • PCR106 Merging Adolescent and Adult Preference Data Into a Potential Latent Scale EQ-5D-Y-3L Value Set: A Latent Class Approach to Analyze Contribution of Each Group to the Preference Weights

    Dec 1, 2023, 00:00

  • EE440 Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Indian Adults Aged ≥60 Years

    Dec 1, 2023, 00:00

  • EE236 The Economic Impact of Third Line Chronic Phase Chronic Myeloid Leukemia Treatment in Greece From a National Payer Perspective

    Dec 1, 2023, 00:00

  • HPR128 Addressing Bias in Health Applications: A Path Towards Health Equity

    Dec 1, 2023, 00:00

  • EE185 Economic Burden of Chlamydia Trachomatis: A Targeted Literature Review and Gap Analysis

    Dec 1, 2023, 00:00

  • MSR73 Methods for Incorporating External Eviden A Comparison of Their Impact on Extrapolations and Uncertainty Estimates Using a Melanoma Case-Study

    Dec 1, 2023, 00:00

  • PCR78 Establishing Meaningful Change Thresholds for EORTC QLQ-CLL17 Domain Scores: An Analysis Based on the TRANSCEND CLL 004 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Dec 1, 2023, 00:00

  • SA31 Systematic Versus Rapid Reviews: The Impact of Different Methodologies on the Reviews’ Conclusions

    Dec 1, 2023, 00:00

  • HPR90 Global Disparities in P4P Programs for Diabetes Care: A Comprehensive Analysis

    Dec 1, 2023, 00:00

  • PCR263 Design of a Patient-Informed Chronic Kidney Disease (CKD) Experience Interview Guide: Learnings From DISCOVER CKD

    Dec 1, 2023, 00:00

  • EE666 Cost-Effectiveness of Duvelisib Versus the Bendamustine Plus Rituximab Regimen for Relapsed/Refractory Follicular Lymphoma Patients in China

    Dec 1, 2023, 00:00

  • HSD132 Analysis of Factors Affecting Medication Adherence in Patients with Hypertension in South Korea

    Dec 1, 2023, 00:00

  • HSD122 A Systematic Review on Equal Access to Treatment for Hearing Loss in Chile: Do All People Have the Same Opportunities to Receive Appropriate Treatment?

    Dec 1, 2023, 00:00

  • EE66 Cost Effectiveness Analysis of Pembrolizumab as First-Line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer in Greece

    Dec 1, 2023, 00:00

  • RWD140 Quality of Electronic Health Records: Encountering Misclassification

    Dec 1, 2023, 00:00

  • HTA86 Factors Affecting Time to Reimbursement of Novel Anticancer Drugs in Ireland

    Dec 1, 2023, 00:00

  • PCR191 Assessing Quality of Care in Haemophilia Using a Value-Based Healthcare Approach

    Dec 1, 2023, 00:00

  • CO54 Recurrence-Free Survival (RFS) as a Surrogate Endpoint (SE) for Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)

    Dec 1, 2023, 00:00

  • PCR244 Core Oncology Outcome Strategies: Do They Offer an Opportunity for Simplicity and Consistency, or Pose a Risk to Comprehensive Understanding of Patient Experiences?

    Dec 1, 2023, 00:00

  • HPR74 Analysis of the Guangdong-Hong Kong-Macau Greater Bay Area Urgent-Use Medicine Scheme—An Opportunity for Early Access in Mainland China

    Dec 1, 2023, 00:00

  • EE243 Utilization of Healthcare Resources and Costs of Hemolytic Disease of Fetus and Newborn (HDFN) in Israel

    Dec 1, 2023, 00:00

  • EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age

    Dec 1, 2023, 00:00

  • EE346 Evaluating the Economic Burden of Osteoporosis in the United States: Insights from a MEPS-Based Analysis

    Dec 1, 2023, 00:00

  • HPR15 Review and Evaluation of Health Equity Considerations in Health Technology Assessments in Cystic Fibrosis

    Dec 1, 2023, 00:00

  • EPH22 Mean Time on Triptan Treatment Among Danish Migraine Patients Before Discontinuing Treatment—A Register-Based Study

    Dec 1, 2023, 00:00

  • EE139 The Need for Economic Systems Modelling to Assess the True Value of Healthcare Innovations: An Application to Influenza Vaccinations

    Dec 1, 2023, 00:00

  • EE27 Risk, Use, and Cost of Infection-Related Hospitalization of Individuals With Alzheimer’s Disease or Dementia

    Dec 1, 2023, 00:00

  • SA56 Treatment Patterns of Advanced Egfr-Positive Non-Small Cell Lung Cancer (NSCLC) in Latin America

    Dec 1, 2023, 00:00

  • Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis

    Dec 1, 2023, 00:00

  • HSD47 Value for Money of Multidisciplinary Programs for Integrated Care in Dialysis: Being Actively Involved and No Merely Listed Matters

    Dec 1, 2023, 00:00

  • RWD163 The Economic Burden of Cutaneous Malignant Melanoma in Gree Analysis of Real-Word Health Insurance Data

    Dec 1, 2023, 00:00

  • EPH103 Estimating the Burden of Vaccine-Preventable Respiratory Diseases Without Vaccination Alternatives in Europe: What's Going on in Spain and Germany?

    Dec 1, 2023, 00:00

  • RWD102 The Real-World Effectiveness of Tixagevimab and Cilgavimab in Immunocompromised Patients: A Single Center Study in Taiwan

    Dec 1, 2023, 00:00

  • MT69 Early Health Economic Modelling to Support the Development of Lifechamps Digital Platform for Older Cancer Survivors

    Dec 1, 2023, 00:00

  • EE294 Public Health Impact and Cost-Effectiveness of Recombinant Zoster Vaccination Among 50 Years Old or Older in Austria

    Dec 1, 2023, 00:00

  • EE317 Microsimulation Model in Obesity: A Feasibility Study Using Object-Oriented C++ Code

    Dec 1, 2023, 00:00

  • MT71 Modelling the Value of Integrating Digital Cellular Pathology in the United Kingdom

    Dec 1, 2023, 00:00

  • HTA117 A Comparison of Health Technology Appraisal (HTA) Timelines and Requirements for Orphan Technologies in 10 European Countries

    Dec 1, 2023, 00:00

  • EE76 End-of-Life Cost and Characteristics of Acute Myeloid Leukemia Decedents: A National Study From 2011-2020

    Dec 1, 2023, 00:00

  • HTA82 Surrogate Measures and the Health Technology Assessment of Cancer Drugs in Ireland: A Retrospective Analysis of EMA Cancer Drug Indication Approvals Between 2017 and 2022 and Recommendations Made By the NCPE in Ireland

    Dec 1, 2023, 00:00

  • HTA139 Uptake of Early Heath Technology Assessment in the United Kingdom: A Literature Review of Empirical Studies

    Dec 1, 2023, 00:00

  • EE687 Cost Analysis of Prostav®: A New Telomere-Based Biomarker for the Early Detection of Prostate Cancer Available in Europe

    Dec 1, 2023, 00:00

  • HTA118 Estimands in Health Technology Assessments: Methodological Considerations and Recommendations

    Dec 1, 2023, 00:00

  • HSD66 Treatment Pathway and Unmet Needs of Waldenström Macroglobulinemia: An Exploratory Study from Portugal

    Dec 1, 2023, 00:00

  • HSD15 Investigating the Impact of Early Versus Late Diagnosis in Fabry Disease on Healthcare Resource Utilization and Associated Costs in Greece

    Dec 1, 2023, 00:00

  • EE445 Economic Evaluation of Alternative Measles-Mumps-Rubella Childhood Vaccination Schedules in Denmark

    Dec 1, 2023, 00:00

  • MT51 Does Current Reimbursement Drive the Adoption of Computer-Aided Applications to Increase the Adenoma Detection in Colonoscopies – a Provider-Based Impact Model for Germany, France, and Italy

    Dec 1, 2023, 00:00

  • EE77 The Cost-Effectiveness of Tradition Chinese Medicine Icaritin Versus Cinobufotalin in Patients with Unresectable Advanced Hepatocellular Carcinoma in China

    Dec 1, 2023, 00:00

  • MT9 The Role of HTA Agencies in Relation to Medical Technologies: A Discourse Analysis

    Dec 1, 2023, 00:00

  • HTA14 Expanding the HTA Cost-Effectiveness Analyses for CheckMate 9LA: Nivolumab Plus Ipilimumab Plus Chemotherapy As First-Line Strategy for Non-Small Cell Lung Cancer

    Dec 1, 2023, 00:00

  • EE621 Cost-Effectiveness Analysis of iGlarLixi Compared With Basal Bolus Insulin Regimen in Triple Metabolic Goal in Type 2 Diabetes Mellitus in Latin America

    Dec 1, 2023, 00:00

  • EPH57 The Market Dynamics of GP IIb/IIIa Inhibitors in Germany: A Closer Look at Eptifibatide and Aggrastat

    Dec 1, 2023, 00:00

  • CO24 Daratumumab in Combination with Lenalidomide and Dexamethasone Improves Survival in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: A Parametric Network Meta-Analysis in a United Kingdom Setting

    Dec 1, 2023, 00:00

  • EPH167 The Conceptualization of Cardiometabolic Disease Policy Model in the UK

    Dec 1, 2023, 00:00

  • EE297 Healthcare Resources Utilization Among Sectors in Saudi Arabia

    Dec 1, 2023, 00:00

  • EE750 Budget Impact Analysis (BIA) of Increased COVID-19 Booster Vaccinations in Austria

    Dec 1, 2023, 00:00

  • EPH28 Burden of Chronic Lymphocytic Leukemia in the United States: A Review of Literature

    Dec 1, 2023, 00:00

  • HTA174 Single-Arm Studies in Rare Diseases and Statistical Methods to Mitigate Lack of Comparative Data: What Kind of Assessment Is More Successful for the French HTA Body?

    Dec 1, 2023, 00:00

  • EE267 Cost-Effectiveness of a Web-Based Interactive Therapeutic Education Platform: Evidence From a Randomized Clinical Trial for Patients With End-Stage Renal Disease

    Dec 1, 2023, 00:00

  • HPR42 A Review of Approved Managed Entry Agreements in Sweden

    Dec 1, 2023, 00:00

  • EPH191 Iron Deficiency Anemia Is Associated with Colorectal and Stomach Cancer Diagnoses in Germany

    Dec 1, 2023, 00:00

  • MSR130 Current Trends in Quantitative Bias Analysis for Unmeasured Confounders: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • EE103 Cost-Effectiveness Analysis of Single-Inhaler Triple Therapy (FF/UMEC/VI) in COPD Using the Fulfil Trial: China Medical Insurance System Perspective

    Dec 1, 2023, 00:00

  • EE383 Cost-Effectiveness Analysis of Nivolumab Plus Relatlimab (NIVO+RELA) Versus Nivolumab Monotherapy (NIVO) for Patients With Advanced Melanoma in the Netherlands

    Dec 1, 2023, 00:00

  • HTA21 A Retrospective Review of Recent NICE Technology Appraisals From 2021 to 2023 to Investigate the Consideration and Acceptability of Cure Modelling Assumptions

    Dec 1, 2023, 00:00

  • RWD132 Impact of Exacerbations on Disease Burden of COPD: A Retrospective Observational Database Cohort Study in Tianjin, China

    Dec 1, 2023, 00:00

  • HSD67 How Can a Digital Twin Help Achieve Technical Efficiency? an Application to the French Medical Genomics Pilot Sequencing Platform Auragen

    Dec 1, 2023, 00:00

  • HTA168 Widening the Value Lens for Child Health Technologies: Development of a Child-Tailored HTA Value Assessment Framework Using Multi-Criteria Decision Analysis Incorporating Patient, Public, and Expert Perspectives

    Dec 1, 2023, 00:00

  • EPH10 ICD-10 Surrogates of the Modified Frailty Index Predict Hospital Referrals in Outpatients Followed in German General Practices

    Dec 1, 2023, 00:00

  • PCR261 Uncovering Patient-Reported Outcome Differences Between Undiagnosed and Diagnosed Individuals With Moderate to Severe Psoriasis in Europe

    Dec 1, 2023, 00:00

  • CO102 Physician Reported Treatment Attributes Considered in First-Line and Perceptions Around Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the US

    Dec 1, 2023, 00:00

  • PCR223 Characterizing Spillover Effects and Carer Burden in X-Linked Hypophosphatemia

    Dec 1, 2023, 00:00

  • MT33 Cost-Effectiveness Analysis of Watchman FLX Left Atrial Appendage Closure in Patients with Non-Valvular Atrial Fibrillation

    Dec 1, 2023, 00:00

  • PCR204 Impact of Roflumilast Foam 0.3% on Patient-Reported Quality of Life in Seborrheic Dermatitis: An Analysis of Stratum Data for Patients Unresponsive or Intolerant to Topical Corticosteroids

    Dec 1, 2023, 00:00

  • HTA30 Behavioural Structured Expert Elicitation: A Case Study to Inform Hospitalisation Due to Respiratory Syncytial Virus in the UK

    Dec 1, 2023, 00:00

  • HTA236 A Systematic Review of Clinical Efficacy and Safety Data in Penta-Refractory Multiple Myeloma: Findings Indicate the Challenges for HTA Submission

    Dec 1, 2023, 00:00

  • PT23 Is It Possible to Estimate the Welfare Economic Loss to Society of Not Having Value-Based Differential Pricing for Multi-Indication Pharmaceuticals: An Empirical Analysis in Denmark, Norway, and Sweden

    Dec 1, 2023, 00:00

  • HTA152 Multidimensional Evaluation of Inebilizumab in Patients With Neuromyelitis Optica Spectrum Disorder

    Dec 1, 2023, 00:00

  • RWD171 Healthcare Resource Utilization and Cost of Renal Replacement Therapy in Brazil: A Five-Year Procedure-Level Analysis

    Dec 1, 2023, 00:00

  • EPH41 Cardiovascular and Renal Replacement Risks in Patients with Sub-Optimally Treated Anemia of Non-Dialysis-Dependent Chronic Kidney Disease

    Dec 1, 2023, 00:00

  • EPH205 Inside CKD: Predicting the Clinical and Economic Burden of Chronic Kidney Disease in Belgium

    Dec 1, 2023, 00:00

  • EE573 Economic Burden of Chronic Kidney Disease with Type 2 Diabetes in Turkiye

    Dec 1, 2023, 00:00

  • EPH161 Epidemiology Landscape and Impact of Obesity: Multi-Country Results from the Impact-O Study

    Dec 1, 2023, 00:00

  • P56 Trends in Prescription Drug Use Among Adults With Diabetes in the United States From 1999-2018

    Dec 1, 2023, 00:00

  • EPH176 Comorbidities Among Individuals at Risk to Develop Severe Form of COVID-19 in Case of Sars-Cov-2 Infection

    Dec 1, 2023, 00:00

  • PCR153 Pace CKD: The Impact of Chronic Kidney Disease and Dialysis on Caregivers Financial Status, and Work Productivity: Results from a Multinational Survey

    Dec 1, 2023, 00:00

  • Reflecting Parameter Uncertainty in Addition to Variability in Constrained Healthcare Resource Discrete Event Simulations: Worth Going the Extra Mile or a Road to Nowhere?

    Dec 1, 2023, 00:00

  • Projecting the Economic Impact of Compensating Living Kidney Donors in the United States: Cost-Benefit Analysis Demonstrates Substantial Patient and Societal Gains

    Dec 1, 2023, 00:00

  • MSR55 How Different Are EQ-5D-Y Values in Asia? a Comparison Study of Four Jurisdictions

    Dec 1, 2023, 00:00

  • EE327 Cost-Effectiveness of Teduglutide in Adult and Pediatric Patients with Short Bowel Syndrome in Argentina: A Markov Model Analysis

    Dec 1, 2023, 00:00

  • EPH125 A Systematic Literature Review and Meta-Analysis on the Disease Burden of Chikungunya

    Dec 1, 2023, 00:00

  • OP11 What Are the Critical Success Factors for a Biotech’s First Commercialization in Europe to Ensure the Right Decisions Are Made for Their Company, Customers, and Future Patients?

    Dec 1, 2023, 00:00

  • EE420 Cost-Effectiveness of Empagliflozin in Chronic Kidney Disease (CKD) Management in the UK

    Dec 1, 2023, 00:00

  • RWD150 A Prescription Pattern of HIV First-Line Tenofovir Alafenamide-Based Single-Tablet Regimens: A Multi-Institutional Study in Taiwan

    Dec 1, 2023, 00:00

  • EPH196 Prevalence of GI Comorbidities by Age Group Among Patients With Rett Syndrome: An Analysis of Coded EHR and Pharmacy Data and Clinical Notes

    Dec 1, 2023, 00:00

  • EE672 Cost-Effectiveness Analysis of Pembrolizumab for the Adjuvant Treatment of Patients With Renal Cell Carcinoma Who Have Undergone Nephrectomy in Greece

    Dec 1, 2023, 00:00

  • HPR86 Reducing Inequity: Does the New EU Pharmaceutical Legislation Address Challenges to Pharmaceutical Access in Central and Eastern Europe?

    Dec 1, 2023, 00:00

  • PCR207 A Vignette Study to Derive Health-Related Quality of Life Weights for Patients With Steroid Refractory Chronic Graft-Versus-Host Disease Receiving Third Line Therapy in the United Kingdom

    Dec 1, 2023, 00:00

  • OP7 Coverage and Equity of a Patient Support Program for Diabetes During the Pandemic Period in a Middle-Income Country

    Dec 1, 2023, 00:00

  • EPH60 Predictive Value of Gensini Score in Severe Coronary Lesions in Algerian Patients Undergoing Coronary Angiography

    Dec 1, 2023, 00:00

  • EPH87 Real-World Evidence Study on Hemophilia B Treatment with Factor IX and Corresponding Treatment Costs in Finland

    Dec 1, 2023, 00:00

  • MT26 Implications of the Implementation of the Joint Committee Assessment on Launch Planning for Medical Technologies in Europe

    Dec 1, 2023, 00:00

  • HTA104 Data on Patient-Reported Outcomes Is Not a Prerequisite for Achieving an Additional Benefit in German Early Benefit Assessment of New Medicinal Products Approved for Dermatological Diseases

    Dec 1, 2023, 00:00

  • HPR46 Payers’ Perceptions of Current Policy Approaches to Address Antimicrobial Resistance in Europe

    Dec 1, 2023, 00:00

  • PCR162 Talking with Teens: Techniques for Building Rapport with Adolescents in Virtual Qualitative Interviews

    Dec 1, 2023, 00:00

  • P31 Evidence Supporting Regulatory Withdrawals and Quantifying Their Impact on Public Health

    Dec 1, 2023, 00:00

  • HTA71 Bridging the Gap: Exploring the PICO Vs Estimand Frameworks in EU Health Technology Assessment (HTA)

    Dec 1, 2023, 00:00

  • EPH136 Treatment Patterns and Epidemiological Characteristics in Adult Patients With III-IVB HNSCC From a Reference Center in Mexico

    Dec 1, 2023, 00:00

  • EE191 Projecting Costs of Care Burden of Depression Between 2023 and 2032 in Hong Kong: A Time-Inhomogeneous Cohort Markov Model Using Real-World Evidence

    Dec 1, 2023, 00:00

  • EPH45 Exploring the Pandemic's Impact: An Examination of Adolescent and Adult Vaccination Rates in Different Countries During COVID-19

    Dec 1, 2023, 00:00

  • HPR107 Bilateral Price Comparison of 50 Particularly Cost-Intensive Drugs – What Is the Impact of Different Reimbursement Rules?

    Dec 1, 2023, 00:00

  • EPH105 Effects of Abortion Debate on Fertility Intentions of Women of Childbearing Age

    Dec 1, 2023, 00:00

  • HTA56 Unequal Access of Innovative Drug Products Across Canada

    Dec 1, 2023, 00:00

  • HPR115 Patient Access Network: Multi-Stakeholder Shared Policy Strategies for Medical Device Access

    Dec 1, 2023, 00:00

  • HPR202 The Digital Transformation: How Could Artificial Intelligence (AI) Re-Shape Drug Launch?

    Dec 1, 2023, 00:00

  • HTA246 A QALY Is Not a QALY When It Comes to Health Technology Appraisals of Pediatric Rare Diseases

    Dec 1, 2023, 00:00

  • EE625 Time in Range As Alternative to HBA1C Change in the IQVIA Core Diabetes Model

    Dec 1, 2023, 00:00

  • EE308 Cost-Utility Analysis of Universal Neonatal Screening for Critical Congenital Heart Disease Based on Pulse Oximetry in Spain

    Dec 1, 2023, 00:00

  • EE724 Inside CKD: Projecting the Population Level Economic Burden of Chronic Kidney Disease According to Urine Albumin-to-Creatinine Ratio (uACR) Categories

    Dec 1, 2023, 00:00

  • EPH184 The Relevance of Insomnia in Relation to Other High-Impact Pathologies. a Systematic Literature Review

    Dec 1, 2023, 00:00

  • HTA114 How Are Companion Diagnostics Evaluated and Reimbursed in Europe? Comparative Analysis of the EU-4 and UK

    Dec 1, 2023, 00:00

  • EE218 Budget Impact and Cost Minimization Analysis of Phesgo ® (Trastuzumab + Pertuzumab SC) for the Treatment of HER2+ Breast Cancer in the Chilean Public Health System

    Dec 1, 2023, 00:00

  • SA21 Feasibility Assessment of an Indirect Treatment Comparison (ITC) of Sacituzumab Govitecan (SG) Vs Trastuzumab Deruxtecan (T-DxD) in HR+/HER2– Metastatic Breast Cancer (mBC)

    Dec 1, 2023, 00:00

  • EE418 Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Treating Iron Deficiency Anemia in Norwegian Patients With Inflammatory Bowel Disease

    Dec 1, 2023, 00:00

  • EE651 Incremental Cost per Remission in Patients With Rheumatoid Arthritis Who Had Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Colombia

    Dec 1, 2023, 00:00

  • EPH258 Treatment Pattern of Pemphigus Vulgaris in UK : A Retrospective Cohort Study Using Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES)

    Dec 1, 2023, 00:00

  • HTA9 Success Rate of Cancer Drugs Fund Reappraisals

    Dec 1, 2023, 00:00

  • EPH90 The Increasing Incidence of Respiratory Syncytial Virus (RSV) in Ireland

    Dec 1, 2023, 00:00

  • EE340 Cost-Effectiveness Analysis of Molnupiravir Against Standard Care for Treating Mild to Moderate COVID-19 Infection in Singapore.

    Dec 1, 2023, 00:00

  • HTA299 A Review of NICE Technology Appraisals of Oncology Treatments in the Past 2 Years – Model Approaches, End of Life Status, and Recommendation Decisions

    Dec 1, 2023, 00:00

  • EE254 Budget Impact of Telemonitoring (TM)-Enabled Care of Obstructive Sleep Apnea Hypoanpnea Syndrome (OSAH) in the UK

    Dec 1, 2023, 00:00

  • EE178 A Targeted Literature Review of Cost-Utility Analyses for Ulcerative Colitis/Crohn’s Disease Treatment

    Dec 1, 2023, 00:00

  • EE377 Budget Impact Analysis of Implementing a Breast Cancer Screening Program in Bulgaria

    Dec 1, 2023, 00:00

  • RWD93 Quantifying Trends in Price Setting for Traditional and Innovative Advanced Rare Disease Therapies

    Dec 1, 2023, 00:00

  • EPH101 Assessing the Relative Benefits Associated With Developing Vaccines for Nipah Virus Infection and Rift Valley Fever From Local, National, and Global Perspectives

    Dec 1, 2023, 00:00

  • EPH61 Epidemiology of Tumor-Related Hypothalamic Obesity in Germany—A Representative Claims Data Analysis

    Dec 1, 2023, 00:00

  • RWD47 Non-Motor Symptoms Burden and Quality of Life in Patients with Parkinson’s Disease (PD)

    Dec 1, 2023, 00:00

  • The Impact of Cancer Screening Programs on Population Health Outcomes

    Dec 1, 2023, 00:00

  • PCR18 Humanistic Burden in Relapsed or Refractory (R/R) Follicular Lymphoma (FL): A Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • Medication Use and Its Consequences

    Dec 1, 2023, 00:00

  • EE206 Clinical and Economic Evaluation of Atezolizumab + Vemurafenib + Cobimetinib Combination in Treatment of Adult Patients with Metastatic Braf-Positive Melanoma

    Dec 1, 2023, 00:00

  • EPH234 Shedding Light into the Dark of Unknown Cost-of-Illness and Burden-of-Disease Associated with RSV across Age Groups in Austria

    Dec 1, 2023, 00:00

  • EE505 Cost-Effectiveness of Ofatumumab in Treatment of Relapsing Multiple Sclerosis in Turkey

    Dec 1, 2023, 00:00

  • EPH106 Intercultural Approach and Knowledge of Migrant Health Policy in Healthcare Teams and Migrants in Chile

    Dec 1, 2023, 00:00

  • HTA220 Incorporating Environmental Sustainability Considerations into National HTA Assessments: A Landscape Review

    Dec 1, 2023, 00:00

  • EE609 Economic Evaluation and Return-on-Investment (ROI) of Fostering Physical Activity Policies (Simulation With Two Different Tools)

    Dec 1, 2023, 00:00

  • EE78 A Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment Following Complete Resection and Platinum-Based Chemotherapy in Adult Patients With Early-Stage Non-Small Cell Lung Cancer With a High Risk of Recurrence

    Dec 1, 2023, 00:00

  • CO89 Efficacy of Anti-Alzheimer’S (AD) Drugs in Cognitive Improvement: A Network Meta-Analysis (NMA) of Randomized Controlled Trials (RCTS)

    Dec 1, 2023, 00:00

  • EE678 Time and Cost Savings from Adopting an Alternative Dosing Schedule with Pembrolizumab for Patients with Advanced Melanoma in Greece

    Dec 1, 2023, 00:00

  • CO137 Health Outcomes of ALK-Inhibitors in Non-Small Cell Lung Cancer in Real Clinical Practice

    Dec 1, 2023, 00:00

  • RWD50 Evaluation and Improvement of a NHDS Algorithm to Detect Patients With Metastatic Breast Cancer and HER2+ Status Using a RWE NLP-Powered Solution

    Dec 1, 2023, 00:00

  • EE583 Unraveling Modeling Challenges in the Economic Evaluations of Gene Therapies: A Global Review

    Dec 1, 2023, 00:00

  • CO12 5 Years of Real-World Data on the Use of Cladribine Tablets for the Treatments of Multiple Sclerosis in Portugal

    Dec 1, 2023, 00:00

  • CO59 Matching-Adjusted Indirect Comparison (MAIC) of Nivolumab + Relatlimab (NIVO+RELA) Vs. BRAF/MEK Inhibitors for First-Line Treatment of BRAF-Mutant Advanced/Metastatic Melanoma (AMEL)

    Dec 1, 2023, 00:00

  • EE508 Cost Estimation Model of Prevented Recurrences with Atezolizumab in Early Non-Small Cell Lung Cancer in Italy

    Dec 1, 2023, 00:00

  • CO83 Disease Burden of Moderate to Severe Ulcerative Colitis in Chinese Patients Under Current Care: A Model Simulation Study

    Dec 1, 2023, 00:00

  • HTA208 Paradigm Shift or Incremental Change? Real-World Evidence for Health Technology Assessment: A Critical Appraisal

    Dec 1, 2023, 00:00

  • PCR235 Drivers of Treatment Preferences in High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) Patients: Qualitative Interviews to Inform a Patient-Preference Study

    Dec 1, 2023, 00:00

  • MSR3 Comparing Statistical Adjustments to Correct Misclassification of Respiratory Syncytial Virus Infections (RSV) in Claims Data

    Dec 1, 2023, 00:00

  • RWD72 Status of the Art on Global Clinical Trials of Patient-Managed Digital Medical Devices (pDMD): 2023 Original Data Analysis From Multiple Sources

    Dec 1, 2023, 00:00

  • HTA150 Health Technology Assessment of Domiciliary Invasive Ventilation for Adults With Spinal Cord Injuries

    Dec 1, 2023, 00:00

  • Methodological Statistical Research

    Dec 1, 2023, 00:00

  • CO31 Progressive Pulmonary Fibrosis: A Modelling Analysis of Long-Term Progression Based on Inbuild

    Dec 1, 2023, 00:00

  • PCR119 The CaOa-QoL-TS: Development and Validation of an Owner-Completed Health-Related Quality of Life and Treatment Satisfaction Measure in Canine Osteoarthritis

    Dec 1, 2023, 00:00

  • MSR146 Proportional Hazards in Survival Analysis: A Review of the Variation in Determining and Presenting PH in NICE STAs

    Dec 1, 2023, 00:00

  • PCR246 Measuring Treatment Preferences for Patients with Pulmonary Arterial Hypertension (PAH); A Discrete Choice Analysis to Identify Scale Heterogeneity

    Dec 1, 2023, 00:00

  • EE188 A Retrospective Cohort Comparing the Tuberculosis Diagnosis Related Costs and Health Resource Use (HRU) Using a Rapid Nucleic Acid Amplification (NAA) Test Vs. Conventional Tests in China, Followed By a Budget Impact Model

    Dec 1, 2023, 00:00

  • HPR204 Reimbursement Status of Centrally Authorized Drugs in Spain per Therapeutic Area and Orphan Designation

    Dec 1, 2023, 00:00

  • MSR8 Nesting a Decision Tree into a Markov Model Structure: An Alternative Way of Tracking Movement in a Diagnostic Model

    Dec 1, 2023, 00:00

  • HTA247 Focus on Two Years of Economic Opinions on Orphan Drug: What Are the Specific Features?

    Dec 1, 2023, 00:00

  • EPH248 Varying Latency Impact on Incidence of Second Primary Malignancy Among Patients with B-Cell Malignancy

    Dec 1, 2023, 00:00

  • EE393 The Cost-Effectiveness of Atidarsagene Autotemcel (Arsa-Cel) for the Treatment of Metachromatic Leukodystrophy (MLD) in the US

    Dec 1, 2023, 00:00

  • CO87 Lifetime Cumulative Risk of Bone Fracture in Chinese Male Patients with Osteoporosis: A Model Simulation Study

    Dec 1, 2023, 00:00

  • HSD111 Real-World Treatment Patterns of Ankylosing Spondylitis

    Dec 1, 2023, 00:00

  • HPR169 The Impact of Exercise on Health Expenditure in Children

    Dec 1, 2023, 00:00

  • HPR152 Evolution of the Use of Medicines in Special Situations and Management Measures for Their Rational Use

    Dec 1, 2023, 00:00

  • HSD44 Healthcare Resource Utilization of Severe Eosinophilic Asthma Patients Treated With Benralizumab in Real-Life: Results From the Portuguese BETREAT Study

    Dec 1, 2023, 00:00

  • HTA295 Insights From Economic Evaluations in Emerging Infection Diseases in Fran Focus on COVID-19

    Dec 1, 2023, 00:00

  • EE292 Cost Effectiveness Analysis of Recombinant Zoster Vaccine Among 50 Years Old and Older in Sweden

    Dec 1, 2023, 00:00

  • EE341 Cost-Utility Analysis of a Multi-Center, Parallel Group Randomized Controlled Trial of an Adapted Parenting Intervention (EPICC-ID) to Reduce Challenging Behavior in Pre-Schoolers with Moderate to Severe Intellectual Disability

    Dec 1, 2023, 00:00

  • PCR118 Cross-Sectional Measurement Properties of the Physical Distancing Scale – COVID-19 (PDS-C19) Self- and Observer-Reported Measure of Physical Distancing Behaviors to Avoid COVID-19 in Adults, Children, and Caregivers

    Dec 1, 2023, 00:00

  • HTA83 Economic Evaluations in Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Challenges for Health Technology Assessment (HTA) Submissions

    Dec 1, 2023, 00:00

  • P7 International Reference Pricing and Joint Clinical Assessments—How Will European-Level HTA Evaluations Impact International Reference Pricing and Launch Sequencing?

    Dec 1, 2023, 00:00

  • MT12 Comparison of Hospital Case Characteristics of Popliteal Artery Aneurysm Repair with ePTFE Covered Stent Grafts with a Heparin Bioactive Surface and Open Surgical Bypass: Highlights from the 2021 Hospital Dataset in Germany

    Dec 1, 2023, 00:00

  • P38 Forecasting Emergency Department Waiting Times Using Deep Neural Networks

    Dec 1, 2023, 00:00

  • HSD105 Pharmacists' Intervention in Access to Therapeutical Innovation in Portuguese Hospitals

    Dec 1, 2023, 00:00

  • RWD122 First and Second Line Treatment Choices for Endometrial Cancer: ECHOS-A Real-World Study

    Dec 1, 2023, 00:00

  • HTA259 Exploring Collaboration on HTA Methodology for Medical Technologies in the Dutch ZonMw HTA Methodology 2021-2024 Subsidy Program

    Dec 1, 2023, 00:00

  • HTA158 Exploring Efficiency of Living Systematic Literature Review (SLR) Tool for Submissions of Clinical Evidence to National Institute for Health and Care Excellence (NICE) by Combining Interventional and Real-World Evidence (RWE)

    Dec 1, 2023, 00:00

  • RWD5 Body Fatness Associations with Cancer: Retrospective Cohort Study from a Brazilian Health Management Organization (RWE)

    Dec 1, 2023, 00:00

  • CO71 Faricimab Versus Standard of Care in Naive Neovascular Age-Related Macular Degeneration Patients: An Indirect Treatment Comparison Using Individual Level Data

    Dec 1, 2023, 00:00

  • MSR65 The Impact of Censoring Assumptions in the Generation of Individual Patient Data from Kaplan-Meier Estimates

    Dec 1, 2023, 00:00

  • HPR69 Comparison of Price Trends for Medicines Pre- and Post-Early Access in Key Markets (France, UK, Australia)

    Dec 1, 2023, 00:00

  • HPR165 Financial-Based Managed Entry Agreements for Drugs in Romania: From Simple to Complex

    Dec 1, 2023, 00:00

  • PCR182 Patient Preferences for Tumor-Agnostic Therapies: Qualitative Insights and Challenges

    Dec 1, 2023, 00:00

  • EPH148 Disease Burden of Sickle Cell Disease in Saudi Arabia

    Dec 1, 2023, 00:00

  • RWD77 Real-World Data Analysis Showing a Significant Improvement in Glycemic Control of People with T2D in Poland When Using a Blood Glucose Meter Connected to a Mobile Health App

    Dec 1, 2023, 00:00

  • MSR124 Improving the Efficiency of Using the Guyot Algorithm to Construct Pseudo Individual Patient Data From Kaplan-Meier Survival Curves: Standardized Guidance and Data Preparation

    Dec 1, 2023, 00:00

  • HTA178 Using Mixed-Methods Development-Focused HTA and Npv Calculations to Guide Further Investment and RD: A Case Study on Establishing the Value Proposition for Biosensor-Integrated Self-Reporting Arteriovenous Grafts

    Dec 1, 2023, 00:00

  • EE733 Distributional Cost-Effectiveness Analysis: A Case Study on Its Potential Prospects in HTA

    Dec 1, 2023, 00:00

  • HPR134 Ethical Considerations in Pay-for-Performance Programs for Diabetes

    Dec 1, 2023, 00:00

  • PT16 Impact of Data Maturity on the Estimation of the within-Trial Hazard Function: An Example from Metastatic Castration Resistant Prostate Cancer

    Dec 1, 2023, 00:00

  • MT43 Does Real-World Evidence Play a Role in Decision-Making by HTA Bodies for Medical Technologies?

    Dec 1, 2023, 00:00

  • EPH212 The Acceptability of Human Papillomavirus Vaccination in the United Kingdom: A Review of the Literature on Barriers and Facilitators to Vaccination

    Dec 1, 2023, 00:00

  • EE411 Cost-per-Responder Analysis of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis

    Dec 1, 2023, 00:00

  • HTA193 Benefits Not Captured in the Quality-Adjusted Life Year Calculation: What Role Do They Play in the National Institute for Health and Care Excellence's Updated Decision-Making Process?

    Dec 1, 2023, 00:00

  • P44 Seeing it in the Flesch: Comparing Readability Between AI-Generated and Human-Written Plain-Language Abstracts

    Dec 1, 2023, 00:00

  • PCR138 An International Study of Patient and Caregiver-Reported Burden and Quality of Life in Wiskott-Aldrich Syndrome

    Dec 1, 2023, 00:00

  • MSR111 Causal Inference and Statistical Considerations for Indirectly Comparing Time-to-Event Endpoints for Treatments with Different Starting Points for Outcome Assessment in Resectable NSCLC

    Dec 1, 2023, 00:00

  • RWD36 Immunoglobulin Use in France 2015 to 2022–Real-World Data From the French Claims Database

    Dec 1, 2023, 00:00

  • PCR272 Qualitative Research to Explore Womens Experience of Vasomotor Symptoms and Evaluate the Suitability of Patient-Reported Outcomes

    Dec 1, 2023, 00:00

  • CO20 Use of Inpatient Systemic Chemotherapy and/or Radiotherapy and Related Predictive Factors for Metastatic Urothelial Cancer (mUC): Findings from a Retrospective Observational Study in a Clinical Practice Setting in Italy

    Dec 1, 2023, 00:00

  • HTA351 A Targeted Review Exploring How English and German Health Technology Assessment Agencies Differ in Their Appraisal of Digital Health Apps

    Dec 1, 2023, 00:00

  • SA79 Opportunities and Challenges for Decentralized Clinical Trials: European Health Technology Assessment Perspective

    Dec 1, 2023, 00:00

  • HTA198 Comparisons of Economic Evaluation Guidelines Between Japan and Six Countries (England, France, Germany, Sweden, Canada and Australia)

    Dec 1, 2023, 00:00

  • HSD57 Adherence Teleassistance-Based Program Impact in a Real-Life Diabetes Colombian Patient Cohort

    Dec 1, 2023, 00:00

  • How Do Patients With Type 2 Diabetes Mellitus Value the Importance of Outcomes? An Overview of Reviews

    Dec 1, 2023, 00:00

  • EE408 Pharmacoeconomic Analysis of Abrocitinib in Patients with Severe Atopic Dermatitis Versus Systemic Treatments in Spain

    Dec 1, 2023, 00:00

  • P23 Evolving Use of Artificial Intelligence and Machine Learning in Systematic Literature Reviews (SLRs)

    Dec 1, 2023, 00:00

  • EE415 Effect of Vitamin C Use on Cost of Common Cold in Turkiye

    Dec 1, 2023, 00:00

  • CO132 A Real-World Evidence Analysis of the Impact of Patient-Physician Sex Concordance on Cancer Treatment Practices and Outcomes

    Dec 1, 2023, 00:00

  • HTA235 Comparative Narrative Review of Oncology Value Assessment Frameworks: Enfortumab Vedotin (EV) for Treatment of Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

    Dec 1, 2023, 00:00

  • CO168 A Propensity Score-Based Comparison of Tepotinib Versus Immunotherapy with/without Chemotherapy, Using Real-World Data in Previously Untreated Met Exon 14 (METEX14) Skipping Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2023, 00:00

  • PCR247 Is the Symptomatology of Infantile Tay-Sachs and Infantile Sandhoff Disease Identical? Data from an International Registry

    Dec 1, 2023, 00:00

  • HTA186 Accelerating Access to Medical Technologies: An Overview of the NICE Early Value Assessment Pilot Project in the UK

    Dec 1, 2023, 00:00

  • HTA243 Guidelines for Incorporating the Societal Perspective and Wider Societal Benefits in Health Technology Assessment

    Dec 1, 2023, 00:00

  • MSR53 Flexsurv Methods to Estimate Cure: An Exploration of Methods for Modelling Cure

    Dec 1, 2023, 00:00

  • HTA39 A Valuable Perspective on Medical Devices – Assesing the Organizational Impact of Health Technologies in Decision-Making

    Dec 1, 2023, 00:00

  • HPR47 Pricing Lottery or Reasonable Algorithm? Insights From the DiGA Arbitration Board

    Dec 1, 2023, 00:00

  • HPR154 When Could a Managed Entry Agreement Create a Win-Win-Win Situation - Exploring the Window of Opportunity

    Dec 1, 2023, 00:00

  • PCR41 The Impact of Moderate to Severe Chronic Hand Eczema and the Effect of Improved Clinical Symptoms on Work Productivity Loss: Data from the DELTA 1 and DELTA 2 Phase 3 Trials

    Dec 1, 2023, 00:00

  • HTA46 Relationship Between the Directness of the Evidence and Identification of Added Therapeutic Value: An Analysis of HTA Procedures

    Dec 1, 2023, 00:00

  • PCR187 Patient-Reported Outcomes in Phase III Randomized Controlled Trials Evaluating First-Line Treatments in Advance/Metastatic Renal Cell Carcinoma: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • RWD87 Retrospective Observational Study of Patients with Metastatic Merkel Cell Carcinoma (mMCC) Using the Caraderm Database Linked to the French National Health Data System (SNDS)

    Dec 1, 2023, 00:00

  • CO100 Regular Laboratory Checks for Ileostomy Patients After Surgery Are Not Performed Comprehensively, but Could Result in Better Health Outcomes

    Dec 1, 2023, 00:00

  • HPR163 Underinvestment in Pharmaceutical Care and Unmet Pharmaceutical Needs Among Older European Adults

    Dec 1, 2023, 00:00

  • EE743 Cost Utility Analysis of Influenza Vaccine Among People Aged 50 Years and Older Living with Comorbidities in Egypt

    Dec 1, 2023, 00:00

  • EE391 The Economic Burden of Varicella Among Children in Fran A Societal Perspective

    Dec 1, 2023, 00:00

  • MT18 Endovascular Management of Iliac and Aorto-Iliac Aneurysms and Impact on Morbidity/Mortality in Fran A French National Insurance Claims Database Analysis (SNDS)

    Dec 1, 2023, 00:00

  • Economic Evaluation

    Dec 1, 2023, 00:00

  • MSR45 Evaluation of the Future Impact of Immuno-Oncology Introduction on Cancer Mortality in Italy

    Dec 1, 2023, 00:00

  • EE75 Cost Analysis of Managing Brain Metastases in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer in Greece

    Dec 1, 2023, 00:00

  • RWD120 Analysis of the Impact of National Medical Insurance Negotiation Policy on the Accessibility of Anti-Cancer Drugs in a City in China

    Dec 1, 2023, 00:00

  • EE390 Optimizing the Use of Risk Factors to Guide the Cost-Effective Use of Palivizumab Prophylaxis Against Severe Respiratory Syncytial Virus Infection in Korean Infants Born 32–35 Weeks’ Gestational Age

    Dec 1, 2023, 00:00

  • HSD30 Real-World Prescribing of GLP-1s Among Patients With Overweight or Obesity in the United States

    Dec 1, 2023, 00:00

  • MT75 Analysis of Manufacturer and Negotiated Price Differential of Digital Health Applications (DIGA) in Germany

    Dec 1, 2023, 00:00

  • HTA352 The Significance of Literature Reviews in the Process of Decision-Making by the Haute Autorité De Santé

    Dec 1, 2023, 00:00

  • HTA4 The Challenges of Health Economic Modeling for Mental Health, Behavioral, and Neurodevelopmental Conditions

    Dec 1, 2023, 00:00

  • EPH9 Non-Alcoholic Fatty Liver Disease Awareness in the United States: National Health and Nutrition Examination Survey Data 1999-2020

    Dec 1, 2023, 00:00

  • CO52 Comparative Analysis of Tabelecleucel Versus Standard of Care in Patients with EBV+ PTLD Following Hematopoietic Cell Transplant (HCT) or Solid Organ Transplant (SOT)

    Dec 1, 2023, 00:00

  • EE182 Costs and Health Impact of Wastewater Surveillance to Guide Respiratory Syncytial Virus Prophylaxis in Canada, Compared to Clinical Surveillance

    Dec 1, 2023, 00:00

  • SA83 {Maicplus}: An R Package to Support Analysis and Reporting of Matching Adjusted Indirect Treatment Comparisons (MAIC) for HTA Dossiers

    Dec 1, 2023, 00:00

  • EE143 Cost-Effectiveness of Replacing the Sequence PCV13→PPV23 with PCV20 in the French Adult Pneumococcal Vaccination Program

    Dec 1, 2023, 00:00

  • EE329 Budget Impact Analysis of Adding Risankizumab and Upadacitinib for the Treatment of Inflammatory Bowel Disease in the Kingdom of Saudi Arabia

    Dec 1, 2023, 00:00

  • HPR5 Implementing a Value-Based Payment Model for Patients with Osteoarthritis

    Dec 1, 2023, 00:00

  • MSR147 Accounting for Study Heterogeneity When Modelling the Multi-State Natural History of Rare Diseases

    Dec 1, 2023, 00:00

  • RWD29 Development of a Comprehensive List of Immunosuppressive Therapies to Enable a Multi-Data Source Global Real-World Effectiveness (RWE) Program of Immunocompromised Patients

    Dec 1, 2023, 00:00

  • EE485 Cost-Effectiveness of a 4 Days-a-Week Triple Therapy in Persons Living with HIV: An Ancillary Study of the Anrs 170 Quatuor Noninferiority Trial

    Dec 1, 2023, 00:00

  • EE270 Predicting Persistent Severe Acute Kidney Injury (AKI) Using the Urinary C-C Motif Chemokine Ligand 14 Biomarker (CCL14). Cost-Utility Analysis in Spain and the UK

    Dec 1, 2023, 00:00

  • HTA313 The Same but Different: Inconsistencies in Key Cost-Effectiveness Assumptions for Curative Therapies across Clinically Similar NICE Appraisals

    Dec 1, 2023, 00:00

  • HTA85 Will the New Dutch Criteria for Therapeutic Value for Oncology Drugs Create Inequalities in Access between Countries? a Review of Health Technology Assessment Oncology Submissions.

    Dec 1, 2023, 00:00

  • PT21 Evaluation and Reimbursement of Digital Therapeutics in Germany, France, Belgium and England

    Dec 1, 2023, 00:00

  • EPH241 Labor-Market Affiliation Among Danish Migraine Patients Discontinuing Triptan Treatment—A Register-Based Study

    Dec 1, 2023, 00:00

  • CO175 OCTOPUS: Ambispective Observational Study Describing Diagnosis and Treatment Patterns in Adults with Metastatic NSCLC with BRAF V600E Mutation in Clinical Practice, to Assess Treatment Effectiveness and Quality of Life (TIP)

    Dec 1, 2023, 00:00

  • PCR260 Influence of Disease Activity and Angioedema on EQ-5D-5L Utility Scores in Chronic Spontaneous Urticaria

    Dec 1, 2023, 00:00

  • HSD121 Study of Effective Treatment of Genital Herpes in Women in Ukraine

    Dec 1, 2023, 00:00

  • PCR37 The Impact of Leber’s Heredity Optic Neuropathy (LHON) on Quality of Life (QoL): A Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • MSR129 Web Tool Development to Ease the Process of Performing the Meta-Analysis of Kaplan-Meier Curves Published in Various Studies

    Dec 1, 2023, 00:00

  • HTA302 A Retrospective Analysis of the Impact of Treatment Effect on HTA Outcomes for Oncology Treatments Assessed in France and Germany

    Dec 1, 2023, 00:00

  • EE735 Cost of Chimeric Antigen Receptor (CAR) T-Cell Therapy Related Toxicities

    Dec 1, 2023, 00:00

  • PT31 A Time Series Analysis of Immune Checkpoint Inhibitors Use in Italian Population: 2017-2022

    Dec 1, 2023, 00:00

  • CO101 Multiple Myeloma (MM) Refractory to Lenalidomide: A Systematic Literature Review (SLR) of Randomised Controlled Trials (RCTs)

    Dec 1, 2023, 00:00

  • Reviewer Acknowledgment

    Dec 1, 2023, 00:00

  • PCR4 Impact of Obesity on Health-Related Quality of Life, Sleep, and Work – a Multinational Survey

    Dec 1, 2023, 00:00

  • MT10 Clinical and Economic Impact of Point-of-Care (POC) Molecular Testing in Patients Presenting With Viral Respiratory Symptoms: A Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • EE156 Assessing Treatment Costs and Economic Burden of Major Cardiovascular Conditions in Turkiye

    Dec 1, 2023, 00:00

  • MT49 Cost-Effectiveness Analysis of Farapulse™ Pulsed Field Ablation (PFA) in Patients with Paroxysmal Atrial Fibrillation

    Dec 1, 2023, 00:00

  • PCR28 Facilitating and Accelerating Patient-Centered Outcomes Measures Awareness and Use in Clinical Research in Rare Diseases

    Dec 1, 2023, 00:00

  • EE246 Is It Possible to Reduce the Costs of Care for Pediatric Patients With Hemophilia A and Inhibitors in Trinidad Tobago?

    Dec 1, 2023, 00:00

  • PCR76 Generating Health-State Utility Values in Patients Treated with Second-Line Systemic Therapy for Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

    Dec 1, 2023, 00:00

  • EE309 Cost-Effectiveness of Mavacamten for the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy in the Netherlands

    Dec 1, 2023, 00:00

  • PCR124 Qualitative Exploration of the Patient Experience of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Via Concept Elicitation Interviews with Patients and Neurologists

    Dec 1, 2023, 00:00

  • PCR149 Determination of Ranges of HiSQOL Scores Defining Clinically Meaningful Within-Patient Improvement Thresholds and Severity Levels

    Dec 1, 2023, 00:00

  • HTA362 Being Specific About Analysis Prespecification: Challenges and Opportunities in the Context of EU HTA

    Dec 1, 2023, 00:00

  • CO70 COPD Exacerbations Pre, During, and Post COVID-19 Pandemic in the US

    Dec 1, 2023, 00:00

  • EE41 Cost Effectiveness of Romosozumab Followed by Alendronate Versus Teriparatide in the Treatment of Severe Osteoporosis in Greece

    Dec 1, 2023, 00:00

  • EE683 The Impact of Tumor Treating Fields (TTFields) Therapy Usage on Cost-Effectiveness: An Analysis of the Incremental Cost-Effectiveness Ratio (ICER)

    Dec 1, 2023, 00:00

  • EE715 Faricimab Vs. Standard of Care in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Cost-Utility Analysis in Italy

    Dec 1, 2023, 00:00

  • RWD127 Systemic Treatment of Non-Melanoma Skin Cancers in Fran Real-World Analysis Using French Data from the National Hospitalization Database

    Dec 1, 2023, 00:00

  • HPR12 Assessing COA Label Claims Based on Single-Arm Trials in Rare Diseases: A Review of US FDA Labels

    Dec 1, 2023, 00:00

  • HPR105 Profitability in the Global Pharmaceutical Industry: A Contested Space

    Dec 1, 2023, 00:00

  • HPR164 What Is a Fair Price? A Review of Definitions for Fair Prices of Health Technologies

    Dec 1, 2023, 00:00

  • MSR70 Translation, Cross-Cultural Adaptation, and Psychometric Evaluation of the Brief Illness Perception Questionnaire Into Yoruba Language Among Persons With Chronic Low Back Pain

    Dec 1, 2023, 00:00

  • EE444 Cost-Effectiveness Analysis of Replacing PCV13 with PCV15 in the Pediatric National Immunization Program of Greece

    Dec 1, 2023, 00:00

  • SA63 Planning Phase 3 Clinical Trials More Efficiently Using an Evidence-Mapping Approach

    Dec 1, 2023, 00:00

  • RWD94 Adaptation and Validation of a Natural Language Processing Algorithm to Use in Electronic Health Records to Identify Patients with Progressive Fibrosing-Interstitial Lung Disease in Spain

    Dec 1, 2023, 00:00

  • P36 Towards a Collaborative Value Assessment Framework for Provider-Facing Digital Health Technologies Used in Chronic Disease Management: Findings and Implications

    Dec 1, 2023, 00:00

  • HTA312 The Association of ESMO-Magnitude of Clinical Benefit Scale Scores and Subsidy Decisions of Targeted Therapies for Solid Tumors in Singapore

    Dec 1, 2023, 00:00

  • EE87 Liquid Metformin for Pediatric Patients with Metabolic Syndrome at Risk of Developing DMT2: Cost-Effectiveness Analysis in Mexican Public Health Institutions

    Dec 1, 2023, 00:00

  • EPH203 The Prevalence of Alopecia Areata in Germany: Results of an Insurance Claims Database Analysis

    Dec 1, 2023, 00:00

  • PCR233 Socioeconomic Impact of Muscular Dystrophies on Patients and Their Caregivers in the Czech Republic

    Dec 1, 2023, 00:00

  • PCR72 How to Achieve Comprehensive Care for Breast Cancer? Challenges in Chile from the Voice of Patients

    Dec 1, 2023, 00:00

  • RWD174 Using Real-World Evidence to Quantify Hospital Costs of Subcutaneous Implantable Cardioverter-Defibrillator Infections in the US

    Dec 1, 2023, 00:00

  • EPH163 Dental Preventive Examinations and Caries Prevalence in Children Aged 8-14 Years

    Dec 1, 2023, 00:00

  • HTA210 Characteristics and Outcomes of Health Technology Assessment Submissions for Advanced Therapy Medicinal Products in Europe: Perspective From Non-EU5 Countries

    Dec 1, 2023, 00:00

  • EE688 Case for Clear Communication and Justification of Survival Extrapolation Methodology: A Review of NICE Submissions in Oncology

    Dec 1, 2023, 00:00

  • PCR219 Hungarian Population Norms for the 15D Generic Preference-Accompanied Health Status Measure

    Dec 1, 2023, 00:00

  • MSR81 When Should I Mix? Improving Understanding of the Predictive Behavior of Mixture-Cure Survival Models Informed by Immature Data

    Dec 1, 2023, 00:00

  • EE569 Cost-Effectiveness of Eftrenonacog Alfa in Treatment of Severe Haemophilia B Patients in Turkey

    Dec 1, 2023, 00:00

  • PT17 Modelling Treatment Duration in Psoriasis: Examining Extrapolation Approaches and Implications

    Dec 1, 2023, 00:00

  • HTA119 Mapping a Path to Standardized Evidence Quality Tools Across EU HTA Agencies and NICE: Is EU Joint Clinical Assessment Guidance Falling Behind?

    Dec 1, 2023, 00:00

  • HTA135 Uncertainty in AMNOG Benefit Assessments: Reflection of G-BA's Underlying Motivation to Cause AbD

    Dec 1, 2023, 00:00

  • SA70 Clinical Benefits and Cost-Effectiveness of High-Dose Capsaicin Cutaneous Patches for Peripheral Neuropathic Pain: A Literature Review

    Dec 1, 2023, 00:00

  • EE261 Economic Burden of Hemophilic Arthropathy in Patients with Hemophilia

    Dec 1, 2023, 00:00

  • MSR83 An Overview of “Multinma” Package: Multilevel Network Meta-Regression

    Dec 1, 2023, 00:00

  • PCR196 Factors Associated with Behaviors Measured By the Rett Syndrome Behavior Questionnaire in Rett Syndrome

    Dec 1, 2023, 00:00

  • CO121 Prevalence of Musculoskeletal and Renal Outcomes in Patients With Chronic Hepatitis B Undergoing Antiviral Treatments in a Real-World Setting

    Dec 1, 2023, 00:00

  • PCR259 Patient-Reported Experience Along the Psoriatic Disease Patient Journey in Portugal

    Dec 1, 2023, 00:00

  • PCR167 Persistence and Adherence to Insulin Treatment in Chinese Patients with Type 2 Diabetes: A Real-World Study

    Dec 1, 2023, 00:00

  • RWD147 Real-World Data of Therapeutic Inertia in Diabetes in a Health Care Intitution

    Dec 1, 2023, 00:00

  • EE545 Evaluating the Clinical Burden of Disease and Costs of ANCA-Associated Vasculitis in Spain: Main Findings from the EUVAS Based Registry.

    Dec 1, 2023, 00:00

  • RWD125 A Health-Related Cost and Mortality Comparison Between Early and Late-Stage Lung Cancer: A Retrospective Cohort Study from a Brazilian Health Management Organization (HMO)

    Dec 1, 2023, 00:00

  • PCR193 Health State Utilities Associated with X-Linked Retinitis Pigmentosa in the United Kingdom

    Dec 1, 2023, 00:00

  • EE580 New Anti-CGRP in Fran Estimated Financial Impact of Eptinezumab in Hospitals, a Prospective Stake

    Dec 1, 2023, 00:00

  • EPH55 The Prevalence and Comorbidities of Prurigo Nodularis – A Danish Register-Based Study From 1995 to 2021

    Dec 1, 2023, 00:00

  • EPH81 Clinical Characteristics and Treatment Patterns of Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2023, 00:00

  • EE438 Cost-Effectiveness of Nirsevimab Against Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV LRTD) in the US Birth Cohort

    Dec 1, 2023, 00:00

  • MSR25 Uncertain About Uncertainty in Matching-Adjusted Indirect Comparisons (MAIC)? A Simulation Study to Compare Methods for Variance Estimation

    Dec 1, 2023, 00:00

  • HTA234 How Long Is the Weight? A Framework for Linear Interpolation of the National Institute for Health and Care Excellence (NICE) Severity Weighting in the Context of Probabilistic Sensitivity Analysis (PSA): A Case Study

    Dec 1, 2023, 00:00

  • CO17 How to Assess Nationwide Population-Based Clinical Benefit of Treatments Using Public Information? Immunotherapies Case Study

    Dec 1, 2023, 00:00

  • EPH69 Disease Burden of Patients With Antibiotic-Resistant Bacteria (Extended-Spectrum Beta-Lactamase or Carbapenem-Resistant Enterobacteriaceae) in Korea

    Dec 1, 2023, 00:00

  • EPH185 Healthcare Resource Utilization and Cost Burden Assessment of Patients with Myasthenia Gravis in Denmark, Finland, and Sweden

    Dec 1, 2023, 00:00

  • HTA323 Analyzing Historic Health Technology Assessments (HTAs): Surrogate Endpoints (SEs) in the Interstitial Pneumonia With Autoimmune Features (IPF)/Interstitial Lung Disease (ILD) Therapeutic Domain

    Dec 1, 2023, 00:00

  • RWD172 Strategies for the Rational Use of Biologic Therapies in an Integrated Clinic for Immune-Mediated Skin Diseases

    Dec 1, 2023, 00:00

  • CO105 A Retrospective Study Characterizing Age at Loss of Ambulation Among Patients With Friedreich Ataxia Using Health Administrative Claims Data in the United States

    Dec 1, 2023, 00:00

  • HTA169 Highly Sensible Tactics: Strategic Insights for Navigating Highly Specialised Technology (HST) Topic Selection

    Dec 1, 2023, 00:00

  • EE247 Emicizumab is Cost-Saving for Finnish Hemophilia A Patients with Factor VIII Inhibitors

    Dec 1, 2023, 00:00

  • EPH174 Trends in Hospitalization of Patients with Wilson's Disease in Germany

    Dec 1, 2023, 00:00

  • RWD116 The Economic Burden of Moderate to Severe Rheumatoid Arthritis (RA) in Spain: Interim 6-Month Results

    Dec 1, 2023, 00:00

  • SA59 Clinical Evidence on Acanthamoeba Keratitis Treatments: Systematic Literature Review

    Dec 1, 2023, 00:00

  • SA76 Systematic Literature Review on Economic Burden of Retinitis Pigmentosa (RP) and Visual Impairment in France

    Dec 1, 2023, 00:00

  • HSD125 Non-Dispensed Prescriptions from the Public and Private Health Care Sectors: A Comparative Register Study

    Dec 1, 2023, 00:00

  • EE563 Cost-Effectiveness of the PPARγ Modulator N-Acetyl-Ged-0507-34-Levo (NAC-GED 5%) Versus Benzoyl Peroxide-Adapalene for Moderate to Severe Acne

    Dec 1, 2023, 00:00

  • EE62 Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed By Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer (ETNBC) in France

    Dec 1, 2023, 00:00

  • EE384 Indirect Cost of HPV-Attributable Cancer in the United Kingdom

    Dec 1, 2023, 00:00

  • EE10 Cost Effectiveness of Implantable Cardioverter Defibrillator Therapy Versus Drug Therapy in Patients for 1.5 Primary Prevention in China: An Analysis Using the Improve SCA Study

    Dec 1, 2023, 00:00

  • EE325 Healthcare Resource Use and Costs Associated with Obesity and Obesity-Related Complications in Saudi Arabia

    Dec 1, 2023, 00:00

  • PCR267 Health-Related Utilities Associated with Pneumococcal Disease in the Adult Population: What Do We Know?

    Dec 1, 2023, 00:00

  • CO107 Resource Use Associated with Alpelisib for the Treatment of Patients with PROS: A Modeling Approach

    Dec 1, 2023, 00:00

  • MSR16 Health-Related Quality of Life Multi-Instrument Comparison for the Use in Children Aged 2-4 Years Old

    Dec 1, 2023, 00:00

  • HPR92 Burnt Out or Something More? Investigating Drivers of and Spatial Variation in NHS Staff Turnover Intention

    Dec 1, 2023, 00:00

  • P52 Validation of an Algorithm to Identify Lines of Therapy Among Adult Patients With Endometrial and Ovarian Cancer in a Real-World Dataset

    Dec 1, 2023, 00:00

  • EE81 Cost-Effectiveness of CDK 4/6I for the Treatment of Postmenopausal Patients With Advanced Breast Cancer HR-Positive, HER2-Negative From the Point of View of the Payer of the Public Health System in Panama

    Dec 1, 2023, 00:00

  • HSD104 Comparative Analysis of Legislations and Market Access of Cannabis Medicines in Poland and Ukraine

    Dec 1, 2023, 00:00

  • Award Winners

    Dec 1, 2023, 00:00

  • EE69 Cost-Utility Analysis of Lorlatinib for First-Line Treatment for ALK Positive Advanced Non-Small Cell Lung Cancer in China

    Dec 1, 2023, 00:00

  • EE660 Real-World Economic Burden and Healthcare Resource Utilization (HCRU) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the United States

    Dec 1, 2023, 00:00

  • HSD37 Gender Disparities in Treatment and Costs of Rectal Cancer at the End of Life Phase—An Analysis of German Claims Data

    Dec 1, 2023, 00:00

  • EE707 Modelling the Cost Effectiveness and Budget Impact of Uterine Botulinum Toxin Injections in Severe Dysmenorrhoea: A France Perspective

    Dec 1, 2023, 00:00

  • EPH95 Claims Data Analysis of the Prevalence and Healthcare Resource Utilization of Chronic Kidney Disease-Associated Pruritus in German Hemodialysis Patients

    Dec 1, 2023, 00:00

  • HSD60 Real-World Usage of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with Psoriatic Arthritis in Germany

    Dec 1, 2023, 00:00

  • EE618 Sacubitril/Valsartan Vs Enalapril Use in Hospitalized Patients with Heart Failure in Spain

    Dec 1, 2023, 00:00

  • EPH147 The Costs of Unaddressed Hearing Loss in Chilean Children with Bilateral Microtia and External Auditory Canal Atresia and Cost Effectiveness of Different Treatment Interventions

    Dec 1, 2023, 00:00

  • CO183 Simulated Treatment Comparison and Matching-Adjusted Indirect Comparison of the Efficacy of Eplontersen and Vutrisiran for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

    Dec 1, 2023, 00:00

  • MSR97 Performance of Matching Adjusted Indirect Comparisons for Single-Arm Trials: A Simulation Study

    Dec 1, 2023, 00:00

  • PCR85 Facilitating the Identification of Appropriate Patient-Centered Outcome Measures (PCOMS) in Rare Disease (RD) Clinical Research Using Functional Impacts Matching

    Dec 1, 2023, 00:00

  • HSD7 Longitudinal Analysis of Diagnostic Procedures for Sleep Disorders in the German In-Patient Sector

    Dec 1, 2023, 00:00

  • EE314 Ferric Carboxymaltose in the Treatment of Iron Deficiency in Patients With Heart Failure From the Perspective of Private Health Care System: Cost-Effectiveness Analysis and Budget Impact in Brazil

    Dec 1, 2023, 00:00

  • EE233 Alternatives to Bayesian Network Meta-Analysis in Case of Proportional Hazards Invalidity: Review of HAS Cost-Utility Studies Opinions in France

    Dec 1, 2023, 00:00

  • EE31 Economic Burden of Hospitalized Respiratory Syncytial Virus Infection Among Children in Spain, 2016–2019

    Dec 1, 2023, 00:00
  • «
  • 11
  • 12
  • 13
  • 14
  • 15 (current)
  • 16
  • 17
  • 18
  • 19
  • 20
  • »